Novel Drug Lanifibranor Promising for NASH
Lanifibranor, a first-in-class pan-peroxisome proliferator-activated receptor (PPAR) agonist, has shown promise in the treatment of nonalcoholic steatohepatitis (NASH), an aggressive
Read more
Lanifibranor, a first-in-class pan-peroxisome proliferator-activated receptor (PPAR) agonist, has shown promise in the treatment of nonalcoholic steatohepatitis (NASH), an aggressive
Read moreTreatment of obesity through exercise and diet is unquestionably the foundation of care for patients with nonalcoholic fatty liver disease
Read more